Mid-cap Health Care company Halozyme Therapeutics has logged a 0.6% change today on a trading volume of 837,586. The average volume for the stock is 2,209,257.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. Based in San Diego, United States the company has 350 full time employees and a market cap of $6,662,559,232.
The company is now trading -19.3% away from its average analyst target price of $67.0 per share. The 8 analysts following the stock have set target prices ranging from $47.0 to $79.0, and on average give Halozyme Therapeutics a rating of buy.
Over the last 52 weeks, HALO stock has risen 8.3%, which amounts to a -3.1% difference compared to the S&P 500. The stock's 52 week high is $70.51 whereas its 52 week low is $42.01 per share. Based on Halozyme Therapeutics's average net margin growth of 13.9% over the last 6 years, its core business is on track for profitability and its strong stock performance may continue in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 1,015,324 | 444,091 | 44 | 29.41 |
| 2023 | 829,253 | 281,594 | 34 | 9.68 |
| 2022 | 660,116 | 202,129 | 31 | -65.93 |
| 2021 | 443,310 | 402,710 | 91 | 89.58 |
| 2020 | 267,594 | 129,085 | 48 | 229.73 |
| 2019 | 195,992 | -72,240 | -37 |
